CorMedix Inc.

DB:19KA Stock Report

Market Cap: €592.6m

CorMedix Management

Management criteria checks 2/4

CorMedix's CEO is Joe Todisco, appointed in May 2022, has a tenure of 4.08 years. total yearly compensation is $6.10M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth €3.03M. The average tenure of the management team and the board of directors is 2.3 years and 4.3 years respectively.

Key information

Joe Todisco

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage11.22%
CEO tenure4.1yrs
CEO ownership0.5%
Management average tenure2.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joe Todisco's remuneration changed compared to CorMedix's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$180m

Dec 31 2025US$6mUS$684k

US$162m

Sep 30 2025n/an/a

US$162m

Jun 30 2025n/an/a

US$51m

Mar 31 2025n/an/a

US$17m

Dec 31 2024US$2mUS$639k

-US$18m

Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

Compensation vs Market: Joe's total compensation ($USD6.10M) is above average for companies of similar size in the German market ($USD1.08M).

Compensation vs Earnings: Joe's compensation has increased by more than 20% in the past year.

CEO

Joe Todisco (50 yo)

4.1yrs
Tenure
US$6,101,176
Compensation

Mr. Joseph Todisco, also known as Joe, MBA, is Director of Airway Therapeutics, Inc. from April 13, 2026. Mr. Todisco serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022 and is its Chairm...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Todisco
CEO & Chairman of the Board of Directors4.1yrsUS$6.10m0.51%
€ 3.0m
Elizabeth Masson-Hurlburt
Executive VP2.3yrsUS$3.74m0.082%
€ 485.4k
Kaufman Zelnick
EVP, Chief Legal and Compliance Officer & Corporate Secretary2.5yrsUS$3.77m0.057%
€ 339.7k
Susan Blum
EVP & Chief Financial Officerless than a yearno data0.011%
€ 63.8k
Beth Steinbrenner
SVP & Chief Human Resource Officerless than a yearno datano data
Matthew David
EVP & Chief Business Officerless than a yearUS$1.09m0.035%
€ 204.5k
Donna Ucci
Senior VP & Head of Global Quality4.1yrsno datano data
Tushar Mukherjee
Senior VP & Head of Technical Operations3.4yrsno datano data
Michael Seckler
EVP & Chief Commercial Officerless than a yearno datano data
Peter Sullivan
Senior Vice President of Market Accessno datano datano data
Jared Crandon
Executive Director of Clinical Portfolio Managementno datano datano data
2.3yrs
Average Tenure
51.5yo
Average Age

Experienced Management: 19KA's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Todisco
CEO & Chairman of the Board of Directors4.3yrsUS$6.10m0.51%
€ 3.0m
Myron Kaplan
Lead Independent Director10.2yrsUS$433.25k0.29%
€ 1.7m
Alan Dunton
Independent Director7.3yrsUS$379.25k0.051%
€ 304.1k
Janet Dillione
Independent Director10.8yrsUS$387.25k0.049%
€ 290.6k
Steven Lefkowitz
Independent Director9yrsUS$397.25k0.12%
€ 736.5k
Gregory Duncan
Independent Director5.6yrsUS$379.25k0.049%
€ 289.6k
Bruce Polsky
Member of Scientific Advisor Boardno datano datano data
Saravanan Balamuthusamy
Member of Scientific Advisory Board4.2yrsno datano data
Sara Bonnes
Member of Scientific Advisory Board4.2yrsno datano data
Aru Narendran
Member of Scientific Advisory Board4.2yrsno datano data
Hannah Newman
Member of Scientific Advisory Board4.2yrsno datano data
Jonathan Waitman
Member of Scientific Advisory Board4.2yrsno datano data
4.3yrs
Average Tenure
70yo
Average Age

Experienced Board: 19KA's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 05:50
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CorMedix Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Jason ButlerCitizens JMP Securities, LLC
Jason KolbertD. Boral Capital LLC.